Literature DB >> 26806281

Genetic basis of TNF-α antagonist associated psoriasis in inflammatory bowel diseases: a genotype-phenotype analysis.

P Vedak1, D Kroshinsky1, J St John1, R J Xavier2, V Yajnik2, A N Ananthakrishnan2.   

Abstract

BACKGROUND: Anti-tumour necrosis factor (anti-TNF) biologic associated psoriasis has been reported in inflammatory bowel disease (IBD) patients. However, little is known regarding its pathogenesis. AIM: To identify potential genetic predispositions to anti-TNF associated psoriasis in IBD patients.
METHODS: This retrospective chart review included IBD patients enrolled in a prospective registry. Cases of anti-TNF associated psoriasis and idiopathic psoriasis unrelated to anti-TNF exposure were confirmed by an expert dermatologist. All patients were genotyped on the Illumina Immunochip. A weighted genetic risk score ascertaining genetic pre-disposition towards psoriasis was calculated and overall genetic pre-disposition as well as differential distribution of individual polymorphisms was compared across the three groups.
RESULTS: Our study included 724 IBD patients who initiated anti-TNF therapy and did not develop psoriasis, 35 patients with anti-TNF associated psoriasis, and 38 patients with idiopathic psoriasis. Anti-TNF users who developed psoriasis had a modest but statistically significantly greater psoriasis genetic risk score than anti-TNF controls (mean 0.64 vs. 0.61, P = 0.04), and had a similar genetic risk score as those with idiopathic psoriasis (0.64 vs. 0.62, P = 0.22). Two loci associated with NOS2 and ETS1 genes achieved P < 0.05 when comparing anti-TNF associated psoriasis to anti-TNF controls. Three loci were significantly different between anti-TNF associated psoriasis and idiopathic psoriasis including a polymorphism near NOS2 encoding for inducible nitric oxide synthase that is produced by dendritic cells in skin lesions in psoriasis.
CONCLUSION: Patients with anti-TNF associated psoriasis had a modestly greater genetic pre-disposition towards psoriasis but no single causative polymorphism was identified.
© 2016 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26806281      PMCID: PMC4755796          DOI: 10.1111/apt.13542

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  35 in total

Review 1.  Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature.

Authors:  G Cullen; D Kroshinsky; A S Cheifetz; J R Korzenik
Journal:  Aliment Pharmacol Ther       Date:  2011-09-29       Impact factor: 8.171

Review 2.  Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-α agents.

Authors:  Gionata Fiorino; Silvio Danese; Benjamin Pariente; Matthieu Allez
Journal:  Autoimmun Rev       Date:  2013-06-15       Impact factor: 9.754

Review 3.  Genetic insights into common pathways and complex relationships among immune-mediated diseases.

Authors:  Miles Parkes; Adrian Cortes; David A van Heel; Matthew A Brown
Journal:  Nat Rev Genet       Date:  2013-08-06       Impact factor: 53.242

Review 4.  Optimizing anti-TNF treatments in inflammatory bowel disease.

Authors:  Shomron Ben-Horin; Uri Kopylov; Yehuda Chowers
Journal:  Autoimmun Rev       Date:  2013-06-19       Impact factor: 9.754

5.  Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci.

Authors:  David Ellinghaus; Eva Ellinghaus; Rajan P Nair; Philip E Stuart; Tõnu Esko; Andres Metspalu; Sophie Debrus; John V Raelson; Trilokraj Tejasvi; Majid Belouchi; Sarah L West; Jonathan N Barker; Sulev Kõks; Külli Kingo; Tobias Balschun; Orazio Palmieri; Vito Annese; Christian Gieger; H Erich Wichmann; Michael Kabesch; Richard C Trembath; Christopher G Mathew; Gonçalo R Abecasis; Stephan Weidinger; Susanna Nikolaus; Stefan Schreiber; James T Elder; Michael Weichenthal; Michael Nothnagel; Andre Franke
Journal:  Am J Hum Genet       Date:  2012-04-06       Impact factor: 11.025

Review 6.  New IBD genetics: common pathways with other diseases.

Authors:  C W Lees; J C Barrett; M Parkes; J Satsangi
Journal:  Gut       Date:  2011-02-07       Impact factor: 23.059

Review 7.  Induction or exacerbation of psoriatic lesions during anti-TNF-α therapy for inflammatory bowel disease: a systematic literature review based on 222 cases.

Authors:  Rafael Denadai; Fábio Vieira Teixeira; Flavio Steinwurz; Ricardo Romiti; Rogério Saad-Hossne
Journal:  J Crohns Colitis       Date:  2012-09-07       Impact factor: 9.071

8.  Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment.

Authors:  Cornelia Tillack; Laura Maximiliane Ehmann; Matthias Friedrich; Rüdiger P Laubender; Pavol Papay; Harald Vogelsang; Johannes Stallhofer; Florian Beigel; Andrea Bedynek; Martin Wetzke; Harald Maier; Maria Koburger; Johanna Wagner; Jürgen Glas; Julia Diegelmann; Sarah Koglin; Yvonne Dombrowski; Jürgen Schauber; Andreas Wollenberg; Stephan Brand
Journal:  Gut       Date:  2013-03-06       Impact factor: 23.059

9.  Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity.

Authors:  Lam C Tsoi; Sarah L Spain; Jo Knight; Eva Ellinghaus; Philip E Stuart; Francesca Capon; Jun Ding; Yanming Li; Trilokraj Tejasvi; Johann E Gudjonsson; Hyun M Kang; Michael H Allen; Ross McManus; Giuseppe Novelli; Lena Samuelsson; Joost Schalkwijk; Mona Ståhle; A David Burden; Catherine H Smith; Michael J Cork; Xavier Estivill; Anne M Bowcock; Gerald G Krueger; Wolfgang Weger; Jane Worthington; Rachid Tazi-Ahnini; Frank O Nestle; Adrian Hayday; Per Hoffmann; Juliane Winkelmann; Cisca Wijmenga; Cordelia Langford; Sarah Edkins; Robert Andrews; Hannah Blackburn; Amy Strange; Gavin Band; Richard D Pearson; Damjan Vukcevic; Chris C A Spencer; Panos Deloukas; Ulrich Mrowietz; Stefan Schreiber; Stephan Weidinger; Sulev Koks; Külli Kingo; Tonu Esko; Andres Metspalu; Henry W Lim; John J Voorhees; Michael Weichenthal; H Erich Wichmann; Vinod Chandran; Cheryl F Rosen; Proton Rahman; Dafna D Gladman; Christopher E M Griffiths; Andre Reis; Juha Kere; Rajan P Nair; Andre Franke; Jonathan N W N Barker; Goncalo R Abecasis; James T Elder; Richard C Trembath
Journal:  Nat Genet       Date:  2012-11-11       Impact factor: 38.330

Review 10.  Promise and pitfalls of the Immunochip.

Authors:  Adrian Cortes; Matthew A Brown
Journal:  Arthritis Res Ther       Date:  2011-02-01       Impact factor: 5.156

View more
  7 in total

1.  Stricturing and Fistulizing Crohn's Disease Is Associated with Anti-tumor Necrosis Factor-Induced Psoriasis in Patients with Inflammatory Bowel Disease.

Authors:  Adam V Weizman; Robyn Sharma; N M Afzal; Wei Xu; Scott Walsh; Joanne M Stempak; Geoffrey C Nguyen; Ken Croitoru; A Hillary Steinhart; Mark S Silverberg
Journal:  Dig Dis Sci       Date:  2018-05-08       Impact factor: 3.199

Review 2.  Current clinical issue of skin lesions in patients with inflammatory bowel disease.

Authors:  Tomoya Iida; Tokimasa Hida; Minoru Matsuura; Hisashi Uhara; Hiroshi Nakase
Journal:  Clin J Gastroenterol       Date:  2019-03-05

3.  TNF Inhibitor-Induced Psoriasis: Proposed Algorithm for Treatment and Management.

Authors:  Sara Jiayang Li; Lourdes M Perez-Chada; Joseph F Merola
Journal:  J Psoriasis Psoriatic Arthritis       Date:  2018-11-21

Review 4.  Digestive system in psoriasis: an update.

Authors:  Daniel Pietrzak; Aldona Pietrzak; Dorota Krasowska; Andrzej Borzęcki; Kinga Franciszkiewicz-Pietrzak; Beata Polkowska-Pruszyńska; Maja Baranowska; Kristian Reich
Journal:  Arch Dermatol Res       Date:  2017-09-13       Impact factor: 3.017

5.  The incidence of psoriasis among smokers and/or former smokers inflammatory bowel diseases patients treated with tumor necrosis factor antagonist: A systematic review and meta-analysis.

Authors:  Meiqi Yang; Weixin Liu; Qiuping Deng; Zeng Liang; Qin Wang
Journal:  Medicine (Baltimore)       Date:  2021-10-22       Impact factor: 1.817

6.  Incidence of and Risk Factors for Paradoxical Psoriasis or Psoriasiform Lesions in Inflammatory Bowel Disease Patients Receiving Anti-TNF Therapy: Systematic Review With Meta-Analysis.

Authors:  Wenhui Xie; Shiyu Xiao; Hong Huang; Zhuoli Zhang
Journal:  Front Immunol       Date:  2022-03-01       Impact factor: 7.561

7.  Paradoxical Psoriasis Induced by Anti-TNFα Treatment: Evaluation of Disease-Specific Clinical and Genetic Markers.

Authors:  Agostino Bucalo; Federica Rega; Arianna Zangrilli; Valentina Silvestri; Virginia Valentini; Giorgia Scafetta; Federica Marraffa; Sara Grassi; Elena Rogante; Arianna Piccolo; Salvatore Cucchiara; Franca Viola; Luca Bianchi; Laura Ottini; Antonio Richetta
Journal:  Int J Mol Sci       Date:  2020-10-23       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.